Keep an eye on Altimmune Inc. (ALT).
The stock is pushing higher thanks to more positive data on its COVID candidate.
The company just published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID, adding the candidate “stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract.”
“AdCOVID is designed to offer significant advantages over other COVID-19 vaccine approaches, including intranasal administration, single-dose effectiveness, broad activation of the immune response, and the ability to ship and store the vaccine conveniently and inexpensively,” according to the company.
EARN 58% & MORE Per Trade On Average
& Risk 91% LESS Doing It!
Potentially EARN 6,438% More Per Year By Defying All Of the Regular, Ordinary, Common, Boundaries & Restrictions On Trading & Investing (like our model portfolio)…
…With Speed, Convenience, & FREEDOM!
…& Risk As Little As $300 & NEVER Own A Single Stock or ETF!